Banking Crisis Prompts Postponed Noile-Immune IPO, But Wider Japan Views Mixed
Executive Summary
While the SVB and wider banking crisis has shaken VCs and bioventures in the US and Europe, Japan has mixed view on its impact and the government is keeping an eye on the situation. But one biotech has nevertheless cautiously decided to withdraw from a market listing despite Tokyo Exchange Market approval.
You may also be interested in...
Is SVB Failure A Sign Of More Uncertainty On The Horizon?
The Silicon Valley Bank shutdown was a shock but is not likely to harm the biopharma financial ecosystem long term. The bigger near- to mid-term factor is inflation due to its impact on interest rates.
Chinese Biotech Expects Limited Impact From SVB Aftermath
Favored by venture capital funds, Silicon Valley Bank has served biotech firms conducting transactions in the US. But its collapse is generating a ripple effect on Chinese start-ups already hard hit by a funding crunch.
SVB Failure Could Exacerbate Tight Credit, Drive Biopharma Consolidation
An economist told Scrip that banks could become more cautious about handing out loans to biotech start-ups, driving more M&A in the sector.